Results 51 to 60 of about 7,137 (182)

Meningococcal Sepsis in Patient with Paroxysmal Nocturnal Hemoglobinuria during Pegcetacoplan Therapy

Emerging Infectious Diseases
Complement C5 inhibitors bring an increased risk for Neisseria infections. A novel complement C3 inhibitor, pegcetacoplan, was recently approved to treat paroxysmal nocturnal hemoglobinuria, a condition commonly treated with complement C5 inhibitors. We
Leo Starck, Vuokko Nummi, Eira Poikonen, Anna-Elina Lehtinen, Pia Kivelä, Nathalie Friberg, Jukka Torvikoski, Maija Toropainen, Seppo Meri   +8 more
doaj   +1 more source

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 236-244, July 2026.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

Pregnancy in Classical Paroxysmal Nocturnal Hemoglobinuria and Aplastic Anemia–Paroxysmal Nocturnal Hemoglobinuria: A High-Risk Constellation

Frontiers in Medicine, 2020
Pregnancies in paroxysmal nocturnal hemoglobinuria (PNH) are associated with increased morbidity and mortality. Retrospective studies suggest that outcome has improved with the advent of the complement inhibitor eculizumab.
Ferras Alashkar, Fuat H. Saner, Colin Vance, Ute Schmücker, Dörte Herich-Terhürne, Ulrich Dührsen, Angela Köninger, Alexander Röth   +7 more
doaj   +1 more source

Complement Inhibition in the Clinic: Are We Doing Enough to Protect Patients From Infection?

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Excessive complement activation is implicated in a broad range of diseases. Therapeutic approaches targeting the complement cascade, from pathway‐selective inhibition to terminal blockade, can effectively control disease activity. However, increasing degrees of complement inhibition are associated with a heightened susceptibility to bacterial, viral ...
Serena Bettoni, Ebba Qviberg, Edward Chaloner, Hayley Lavender, Maisem Laabei   +4 more
wiley   +1 more source

Paroxysmal hemoglobinuria

Kazan medical journal, 1930
This rare clinical form deserves to be noted not only as a casuistic material, but also because the patient with this form was sent by the TB dispensary to the sanatorium as a tuberculosis one, after 6 months of observation, with a diagnosis of B-II fibro-productive.
openaire   +1 more source

Complement Factor H‐Based Therapeutics: A Comprehensive Overview

European Journal of Immunology, Volume 56, Issue 7, July 2026.
Complement factor H is a central regulator of the complement system and thus a target for therapeutic intervention. In this review, we provide an overview of past and current factor H‐based therapeutic concepts and modalities to treat complement‐mediated diseases.
Sebastiaan M. W. R. Hamers, Emmy J. Buter, Richard B. Pouw   +2 more
wiley   +1 more source

Long-term outcome of a randomized controlled study in patients with newly diagnosed severe aplastic anemia treated with antithymocyte globulin and cyclosporine, with or without granulocyte colony-stimulating factor: a Severe Aplastic Anemia Working Party Trial from the European Group of Blood and Marrow Transplantation

Haematologica, 2020
This follow-up study of a randomized, prospective trial included 192 patients with newly diagnosed severe aplastic anemia receiving antithymoglobulin and cyclosporine, with or without granulocyte colony-stimulating factor (G-CSF).
André Tichelli, Régis Peffault de Latour, Jakob Passweg, Cora Knol-Bout, Gérard Socié, Judith Marsh, Hubert Schrezenmeier, Britta Höchsmann, Andrea Bacigalupo, Sujith Samarasinghe, Alicia Rovó, Austin Kulasekararaj, Alexander Röth, Dirk-Jan Eikema, Paul Bosman, Peter Bader, Antonio Risitano, Carlo Dufour   +17 more
doaj   +1 more source

Concurrent Loss of PIGA and ZRSR2 in a Patient With Paroxysmal Nocturnal Hemoglobinuria and Myelodysplastic Neoplasm

International Journal of Laboratory Hematology, EarlyView.
Fatma AlBulushi, Eric McGinnis
wiley   +1 more source

Switching between complement inhibitors in paroxysmal nocturnal hemoglobinuria: Analysis of strategy, efficacy, and safety

HemaSphere, Volume 10, Issue 7, July 2026.
Abstract Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra‐orphan disease. In 2026, approved complement inhibitors (CIs) for PNH include three C5 inhibitors (C5i) and three proximal inhibitors (PIs). Clinical trials for the approved PI pegcetacoplan, iptacopan, and C5i + danicopan had clear protocols for changing from terminal to PI, extrapolated ...
Morag Griffin, Bruno Fattizzo, Jong Wook Lee, Richard J. Kelly, Roochi Trikha, Yasutaka Ueda, Jun‐ichi Nishimura, Christopher J. Patriquin, Alexander Röth, Petra Muus, Jens Panse, Miguel Gómez Álvarez, Alexandra Pike, Talha Munir, Shreyans Gandhi, Austin Kulasekararaj   +15 more
wiley   +1 more source

A Case of Paroxysmal Nocturnal Hemoglobinuria (PNH) in an Obstetric Patient: A South African Perspective

Clinical Management Issues, 2019
Paroxysmal Nocturnal Hemoglobinuria (PNH) originates from an acquired genetic defect in a multipotent hematopoietic stem cell that becomes stem-cell-like in its ability to survive, expand, and self-renew.
Garrick Laudin, Lizemarie Wium
doaj   +1 more source